Showing results (101-110 of 127) with videos related to

Sort By:
Pageof 13
Hepatology (Baltimore, Md.)|April 20, 2018
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus InfectionNancy Reau, Paul Y Kwo, Susan Rhee, et al.
The Lancet. Gastroenterology & Hepatology|June 20, 2024
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 studyHarry L A Janssen, Young-Suk Lim, Pietro Lampertico, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysisK Rajender Reddy, Marc Bourlière, Mark Sulkowski, et al.
Journal of Hepatology|July 23, 2022
Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHBMan-Fung Yuen, Stephen Locarnini, Tien Huey Lim, et al.
Gastroenterology|September 28, 2014
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label studyMichael P Curry, Xavier Forns, Raymond T Chung, et al.
Journal of Hepatology|April 17, 2017
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosisPaul Y Kwo, Fred Poordad, Armen Asatryan, et al.
Journal of Viral Hepatitis|November 14, 2018
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysisSteven Flamm, David Mutimer, Armen Asatryan, et al.
Antiviral Research|September 26, 2024
Preclinical and clinical antiviral characterization of AB-836, a potent capsid assembly modulator against hepatitis B virusAngela M Lam, Nagraj Mani, Andrzej Ardzinski, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialMaria Buti, Edward Gane, Wai Kay Seto, et al.
Gastroenterology|October 20, 2010
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis BE Jenny Heathcote, Patrick Marcellin, Maria Buti, et al.
Pageof 13